Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like ParticlesPaul Goepfert, Harriet L. Robinson, John Hural et al.|The Journal of Infectious Diseases|2011Cited by 177
Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 studyYehuda Z. Cohen, Marina Caskey, Allison L. Butler et al.|PLoS ONE|2019Cited by 92
Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like ParticlesPaul Goepfert, Harriet L. Robinson, Marnie Elizaga et al.|The Journal of Infectious Diseases|2014Cited by 84